Related Experiment Video
Updated: Jun 13, 2026

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
Catalytic M1GS RNA as an antiviral agent in animals
Yong Bai1, Paul Jay Fannin Rider, Fenyong Liu
1Program in Comparative Biochemistry, University of California, Berkeley, CA, USA.
Abstract:
The use of RNase P ribozyme (M1GS catalytic RNA) for inhibition of murine cytomegalovirus (MCMV) propagation in mice is described in this chapter. General information about RNase P based technology is included and followed by detailed protocols focused on (1) construction and in vitro cleavage assay of the customized M1GS ribozyme, (2) stable expression of the M1GS RNA and evaluation of its activity in inhibition of viral gene expression and growth in cultured cells, and (3) investigation of M1GS-mediated inhibition of viral infection and pathogenesis in animals. Using these methods, we have successfully constructed catalytic M1-1 RNA against the MCMV assembly protein (mAP) and M80 mRNA. Our recent study has demonstrated that an 80% reduction in the expression of mAP and M80 and a 2,000-fold reduction in viral growth were observed in cells expressing the ribozyme. Furthermore, after the functional ribozyme-expressing constructs were delivered into MCMV-infected SCID mice, a significant reduction of viral gene expression and infection was detected, and the survival of the infected animals was significantly improved. Collectively, our data demonstrate the feasibility of the use of RNase P ribozyme for inhibition of viral gene expression in animals and support the utility of RNase P ribozyme for gene-targeting applications in vivo.
Insights
Catalytic RNase P ribozyme (M1GS) effectively inhibits murine cytomegalovirus (MCMV) replication in cell cultures and SCID mice. This gene-targeting technology shows promise for treating viral infections in vivo.
Area of Science:
- Molecular Biology
- Virology
- Biotechnology
Background:
- Ribozymes, catalytic RNA molecules, offer precise gene targeting.
- RNase P ribozymes can be engineered for specific RNA cleavage.
- Murine cytomegalovirus (MCMV) is a significant pathogen in immunocompromised hosts.
Purpose of the Study:
- To evaluate the efficacy of a customized RNase P ribozyme (M1GS) against MCMV.
- To demonstrate the in vitro and in vivo application of ribozyme technology for viral inhibition.
Main Methods:
- Construction and in vitro cleavage assay of M1GS ribozymes targeting MCMV genes.
- Stable expression of M1GS RNA in cultured cells to assess antiviral activity.
- In vivo studies in SCID mice to evaluate M1GS-mediated inhibition of MCMV infection and pathogenesis.
Main Results:
- Engineered M1GS ribozymes successfully targeted MCMV assembly protein (mAP) and M80 mRNA.
- Significant reduction (80%) in viral gene expression and viral growth (2,000-fold) observed in cell cultures.
- In vivo delivery of M1GS constructs into MCMV-infected mice led to reduced viral gene expression, infection, and improved animal survival.
Conclusions:
- RNase P ribozymes are feasible tools for inhibiting viral gene expression in vivo.
- This gene-targeting strategy holds potential for therapeutic applications against viral infections.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Inhibitors of Viral Protein Synthesis
Experimental RNAi
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Inhibitors Of Virion Release

